Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1993-3-29
|
| pubmed:abstractText |
Recombinant human interleukin-3 (IL-3) is well-tolerated according to phase I studies, and produces trilineage hematologic responses in patients with normal bone marrow. In addition, promising results have been obtained in a variety of bone marrow failure states. We studied IL-3 in 7 patients with markedly delayed engraftment after autologous bone marrow transplantation (ABMT) for hematologic malignancies (acute myeloid leukemia 4, chronic myeloid leukemia 1, myeloma 1, non-Hodgkin's lymphoma 1). All patients were red blood cell- and platelet transfusion-dependent, had an absolute neutrophil count (ANC) < 0.7 x 10(9)/L and failed to achieve a sustained ANC > 1.0 x 10(9)/L after receiving granulocyte-macrophage colony stimulating factor (GM-CSF) for 28 days. IL-3 was given daily for 21 days at 2 micrograms/kg/d (2 patients) and 5 micrograms/kg/d (5 patients). Toxicity was mild and consisted mostly of low-grade fever and malaise. No changes in platelet, hemoglobin or reticulocyte levels were observed. Four patients had at least a 2-fold increase in ANC at the end of IL-3 treatment. Five patients received GM-CSF 10 micrograms/kg/d subcutaneously for 7 to 10 days immediately after IL-3 and 4 had a further increase in ANC (median 1.7-fold, range 1.6- to 5.8-fold), but no change in platelet transfusion requirements. Hematopoietic colony assays of bone marrow cells obtained before and after treatment showed that granulocyte-macrophage colony-forming cell (CFU-GM) and erythroid blast-forming cell (BFU-E) levels were severely reduced and multilineage progenitors (CFU-GEMM) absent in all patients, and remained low after IL-3 treatment for 21 days. Sequential IL-3 and GM-CSF produced a significant but transient increase in the neutrophil counts of some patients. IL-3 appears to be of limited benefit in patients who are severely aplastic after ABMT and have very low levels of bone marrow progenitors.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0301-472X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
21
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
405-410
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8440338-Acute Disease,
pubmed-meshheading:8440338-Adult,
pubmed-meshheading:8440338-Blood Cell Count,
pubmed-meshheading:8440338-Bone Marrow Transplantation,
pubmed-meshheading:8440338-Cell Differentiation,
pubmed-meshheading:8440338-Cell Division,
pubmed-meshheading:8440338-Dose-Response Relationship, Drug,
pubmed-meshheading:8440338-Drug Therapy, Combination,
pubmed-meshheading:8440338-Female,
pubmed-meshheading:8440338-Graft Rejection,
pubmed-meshheading:8440338-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:8440338-Granulocytes,
pubmed-meshheading:8440338-Hematopoiesis,
pubmed-meshheading:8440338-Hematopoietic Stem Cells,
pubmed-meshheading:8440338-Humans,
pubmed-meshheading:8440338-Interleukin-3,
pubmed-meshheading:8440338-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:8440338-Leukemia, Myeloid,
pubmed-meshheading:8440338-Lymphoma, Non-Hodgkin,
pubmed-meshheading:8440338-Male,
pubmed-meshheading:8440338-Middle Aged,
pubmed-meshheading:8440338-Multiple Myeloma,
pubmed-meshheading:8440338-Neutrophils,
pubmed-meshheading:8440338-Recombinant Proteins,
pubmed-meshheading:8440338-Time Factors,
pubmed-meshheading:8440338-Transplantation, Autologous
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
|
| pubmed:affiliation |
University of Toronto Autologous Bone Marrow Transplant Program, Ontario, Canada.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|